Following the approval, Elahere became the first and only FRα-directed antibody drug conjugate (ADC) approved specifically for patients with FRα positive, platinum-resistant ovarian cancer in ...

ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...

AbbVie Inc.'s Q1 earnings highlight an 8.4% revenue boost, driven by Skyrizi & Rinvoq. Click for ABBV's market expansion, ...

AbbVie (ABBV) stock gains as the company lifts 2025 earnings outlook after strong Q1 results, driven by its newer immunology ...

Novartis has done a little spring cleaning, sweeping a phase 2 osteoarthritis prospect and first-in-human radioconjugate out of its pipeline after assessing evidence on the programs. | Novartis has ...

AbbVie Inc. ABBV reported first-quarter 2025 adjusted earnings per share (EPS) of $2.46, which beat the Zacks Consensus ...

These deals added major growth drivers to the company's lineup, including cancer drug Elahere, cosmetic therapy Botox, and antipsychotic Vraylar. In addition, AbbVie's pipeline appears to be ...

AbbVie’s oncology/hematology sales rose 7.5% to $1.63 billion in the quarter, as sales from the recently acquired ovarian cancer drug Elahere and rising Venclexta sales more than offset the ...